Clinical Trials for Luminal Androgen Receptor Breast Carcinoma

Darolutamide Alone or in Combination With Standard Therapy Before Surgery for the Treatment of Stage II-IIIA, Androgen Receptor Positive, Triple-Negative Breast Carcinoma

NCT ID: NCT07016399

This clinical trial is looking at whether adding a medication called darolutamide to standard treatments can help patients with stage II to IIIA triple-negative breast cancer before they have surge...